{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:56:13Z","timestamp":1781510173434,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ahjo.2026.100810","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:15:39Z","timestamp":1780557339000},"page":"100810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["\u03b2-Blockers after myocardial infarction with preserved or mildly reduced left ventricular ejection fraction: Fragility of contemporary evidence"],"prefix":"10.1016","volume":"67","author":[{"given":"Marco","family":"Zuin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Chopard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas E.","family":"Drachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Rigatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Temporelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahjo.2026.100810_bb0005","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.1981.03320180063037","volume":"246","year":"1981","journal-title":"JAMA"},{"key":"10.1016\/j.ahjo.2026.100810_bb0010","first-page":"57","article-title":"Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group","volume":"2","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.ahjo.2026.100810_bb0015","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","article-title":"beta Blockade after myocardial infarction: systematic review and meta regression analysis","volume":"318","author":"Freemantle","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.ahjo.2026.100810_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199347","article-title":"Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention","volume":"13","author":"Watanabe","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ahjo.2026.100810_bb0025","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.amjmed.2014.05.032","article-title":"Clinical outcomes with \u03b2-blockers for myocardial infarction: a meta-analysis of randomized trials","volume":"127","author":"Bangalore","year":"2014","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ahjo.2026.100810_bb0030","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11606-021-06999-9","article-title":"The fragility index for assessing the robustness of the statistically significant results of experimental clinical studies","volume":"37","author":"Ho","year":"2022","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.ahjo.2026.100810_bb0035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamasurg.2018.4318","article-title":"The fragility index in randomized clinical trials as a means of optimizing patient care","volume":"154","author":"Tignanelli","year":"2019","journal-title":"JAMA Surg."},{"key":"10.1016\/j.ahjo.2026.100810_bb0040","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jclinepi.2013.10.019","article-title":"The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index","volume":"67","author":"Walsh","year":"2014","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ahjo.2026.100810_bb0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.12469","article-title":"Application of the reverse fragility index to statistically nonsignificant randomized clinical trial results","volume":"3","author":"Khan","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ahjo.2026.100810_bb0050","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.119.005755","article-title":"Fragility index in cardiovascular randomized controlled trials","volume":"12","author":"Khan","year":"2019","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.ahjo.2026.100810_bb0055","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/j.semtcvs.2022.05.010","article-title":"Reverse fragility index in negative cardiac procedural randomized controlled trials","volume":"35","author":"Dhingra","year":"2023","journal-title":"Semin. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.ahjo.2026.100810_bb0060","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jss.2017.11.061","article-title":"Assessing quality of randomized trials supporting guidelines for laparoscopic and endoscopic surgery","volume":"224","author":"Bowers","year":"2018","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.ahjo.2026.100810_bb0065","doi-asserted-by":"crossref","DOI":"10.1007\/s11606-019-04928-5","article-title":"The fragility index in a cohort of HIV\/AIDS randomized controlled trials","volume":"34","author":"Wayant","year":"2019","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.ahjo.2026.100810_bb0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jclinepi.2019.03.012","article-title":"The statistical significance of meta-analyses is frequently fragile: definition of a fragility index for meta-analyses","volume":"111","author":"Atal","year":"2019","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ahjo.2026.100810_bb0075","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMoa2401479","article-title":"REDUCE-AMI Investigators. Beta-blockers after myocardial infarction and preserved ejection fraction","volume":"390","author":"Yndigegn","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahjo.2026.100810_bb0080","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2505985","article-title":"Beta-blockers after myocardial infarction in patients without heart failure","author":"Munkhaugen","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahjo.2026.100810_bb0085","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2504735","article-title":"Beta-blockers after myocardial infarction without reduced ejection fraction","author":"Ibanez","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahjo.2026.100810_bb0090","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ahjo.2026.100810_bb0095","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahjo.2026.100810_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(25)01592-2","article-title":"\u03b2 blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials","author":"Rossello","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ahjo.2026.100810_bb0105","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJMoa2512686","article-title":"Beta-blockers after myocardial infarction with normal ejection fraction","volume":"394","author":"Kristensen","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ahjo.2026.100810_bb0110","doi-asserted-by":"crossref","DOI":"10.1093\/ehjcvp\/pvaf062","article-title":"Impact of left ventricular ejection fraction on the effect of beta-blocker therapy on one-year mortality in acute coronary syndrome patients","author":"Maeder","year":"2025","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"10.1016\/j.ahjo.2026.100810_bb0115","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.jacc.2025.03.539","article-title":"Reevaluating beta-blocker recommendations post-myocardial infarction: perspective on the 2025 guideline update","volume":"85","author":"Kaul","year":"2025","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602226000984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602226000984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:49:01Z","timestamp":1781509741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666602226000984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":23,"alternative-id":["S2666602226000984"],"URL":"https:\/\/doi.org\/10.1016\/j.ahjo.2026.100810","relation":{},"ISSN":["2666-6022"],"issn-type":[{"value":"2666-6022","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b2-Blockers after myocardial infarction with preserved or mildly reduced left ventricular ejection fraction: Fragility of contemporary evidence","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal Plus: Cardiology Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahjo.2026.100810","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100810"}}